What’s New with GlobalData's Pharmaceutical & HealthCare Industry Reports14 Nov 2011 • by Natalie Aster
Market Publishers Ltd informs that new GlobalData's Pharmaceutical & HealthCare Industry Reports have been added to its catalogue:
GlobalData’s analysis suggests that the global benign prostatic hyperplasia (BPH) therapeutics market was worth $3.2 billion in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 6.4% for the next eight years to reach $5.2 billion by 2018. This growth rate is primarily attributed to the recent and impending patent expiry of Uroxatral and Avodart/Avolve in the US and the EU. However, the strong pipeline is set to offset the depleting revenues with the expected launch of Cialis and NX-1207 in the near future. The increase in the elderly population is expected to be a major driver of the BPH therapeutics market.
GlobalData analyzed the BPH therapeutic pipeline and found it to be strong. The pipeline for BPH therapeutics consists of approximately 21 molecules in different stages of development. More than 80% of the BPH therapeutics pipeline is captured by first-in-class molecules. Most of these molecules hold promise, with a novel mechanism of action and good efficacy and safety profiles. The BPH therapeutics pipeline does not have any me-too molecules. Eli Lilly’s Cialis is one of the most promising molecules that been filed with the US FDA (Food and Drug Administration) for marketing approval to treat BPH. Nymox’s NX-1207 is a novel injectable therapy and is expected to be launched in the US and the EU by 2014, which will drive the saturated BPH therapeutics market.
GlobalData estimates that the global MDD therapeutics market was worth $6.9 billion in 2010 and expected it to grow at a compound annual growth rate (CAGR) of 6% over the next eight years to reach $11 billion by 2018. The MDD therapeutics market will witness the patent expiry of Lexapro in 2012, Cymbalta in 2013 and Effexor XR in 2014. However, the launch of new drugs such as Viibryd, LuAA21004, Levomilnacipran (F2695) and Agomelatine (AGO178) in the US, offering better efficacy and safety profiles, along with disease modifying properties, will help to sustain steady and positive growth during the forecast period to 2018.
GlobalData’s research indicates that the market for MDD therapeutics is well served by the current approved drug classes, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs). The MDD therapeutics market will face the patent expiry of the leading drugs Lexapro (2012), Cymbalta (2013) and Effexor XR (2014). However, the expected launch of Lu AA21004 by Lundbeck, Levomilnacipran (F2695) by Forest Laboratories (in the US and EU5 in 2013) and the launch of Agomelatine (AGO178) by Novartis in the US by 2013, will help maintain a positive growth trend during the forecast period.
Report Per Price: $3,500.00 (Single User License)
More new market research reports by GlobalData can be found at publisher page.
To order the report or ask for sample pages contact email@example.com